Review: TTR amyloidosis - Structural features leading to protein aggregation and their implications on therapeutic strategies

Journal of Structural Biology

Volumn 130, Issue 2-3, 2000, Pages 290-299

  Damas, Ana Margarida ^a,b   Saraiva, Maria João ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

PREALBUMIN;

AMINO ACID SEQUENCE; AMYLOIDOSIS; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN STABILITY; REVIEW;

EID: 0033857583     PISSN: 10478477     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsbi.2000.4273     Document Type: Review

References (71)

1. Thyroxine binding to transthyretin Met 119: Comparative studies of different heterozygotic carriers and structural analysis
2. Human plasma transthyretin (TTR) is composed of many different molecular species with modified stability
3. Electrically neutral microheterogeneity of human plasma transthyretin (prealbumin) detected by isoelectric focusing in urea gradients
4. Potential treatment of transthyretin-type amyloidosis by sulfite
5. Comparative stability and clearance of [Met30] transthyretin and [Met119] transthyretin
6. A peculiar form of peripheral neuropathy: A typical generalized amyloidosis with special involvement of the peripheral nerves
7. Structure of human plasma prealbumin at 2.5 Å resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding
8. Structure of prealbumin: Secondary, tertiary and quaternary interaction determined by Fourier refinement at 1.8 Å
9. Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous β-sheet helix
10. 'In vitro' amyloid fibril formation from transthyretin: The influence of ions and the amyloidogenicity of TTR variants
11. Crystal structure determination at 2.3 Å resolution of human transthyretin-3,5'-dibromo-2',4,4',6-tetrahydroxyaurone complex
12. Familial amyloid polyneuropathy: New developments in genetics and treatment
13. Familial amyloid polyneuropathy: An electron microscope study of the peripheral nerve in five cases
14. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro
15. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy
16. A fiber diffraction study of FAP fibrils
17. Structural studies on FAP fibrils: Removal of contaminants is essential for the interpretation of X-ray data
18. The crystal structure of Val-122-Ile variant transthyretin - A cardiomyopathic mutant
19. Multiple modes of binding of thyroid hormones and other iodothyronines to human plasma transthyretin
20. Characterization of a transthyretin (prealbumuin) variant associated with familial amyloidotic polyneuropathy type II (Indiana/Swiss)
21. New drug therapy of amyloidoses: Resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin
22. Characterization of two highly amyloidogenic mutants of transthyretin
23. The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-Met variant to 1.7 Å resolution
24. Structural changes in transthyretin produced by the Ile 84 Ser mutation which result in decreased affinity for retinol-binding protein
25. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis
26. Ultrastructure of familial amyloid polyneuropathy amyloid fibrils: Examination with high-resolution electron microscopy
27. Analysis of X-ray diffraction patterns from amyloid of biopsied vitreous humor and kidney of transthyretin (TTR) Met30 familial amyloidotic polyneuropathy (FAP) patients: Axially arrayed TTR monomers constitute the protofilament
28. Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement
29. Structural analysis of peptide fragment 71-93 of ansthyretin by NMR spectroscopy and electron microscopy: Insight into amyloid fibril formation
30. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways
31. Enhanced amyloidogenicity of sulfonated transthyretin in vitro, a hypothetical etiology of senile amyloidosis
32. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid
33. Structural basis for the binding of hydroxylated polychlorobiphenyl (PCB) metabolites to human transthyretin
34. Orthotopic liver transplantation for familial amyloidotic polyneuropathy
35. Crystallization and preliminary X-ray data for the human transthyretin-retinol-binding protein (RBP) complex bound to an anti-RBP Fab
36. Plasma transthyretin. Tissue sites of degradation and turnover in the rat
37. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis
38. Treatment of AL amyloidosis with 4'-iodo-4'-deoxydoxorubicin: An update
39. Inhibiting transthyretin amyloid fibril formation via protein stabilization
40. Structure of a complex of two plasma proteins: Transthyretin and retinol-binding protein
41. The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP
42. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors
43. IDOX binding to transthyretin amyloid in tissue sections and synthetic fibrils
44. 4'-Iodo-4'-deoxydoxorubicin (I-DOX) disrupts the fibrillar structure of transthyretin amyloid
45. Inhibiting transthyretin conformational changes that lead to amyloid formation
46. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution
47. The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis
48. Designing transthyretin mutants affecting tetrameric structure: Implications in amyloidogenicity
49. Molecular genetics of familial amyloidotic polyneuropathy
50. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin)
51. Modulating conformational factors in transthyretin amyloid
52. Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: New model for amyloid fibril formation
53. Crystallization and preliminary X-ray diffraction studies of Leu-55-Pro variant transthyretin
54. The crystal structure of amyloidogenic Leu55Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils
55. The mechanism for Leu55Pro transthyretin 'amyloid-like' oligomer disaggregation by 4'-iodo-deoxy doxorubicin
56. Examination of the structure of the transthyretin amyloid fibril by image reconstruction from electron micrographs
57. The 'edge strand' hypothesis: Prediction and test of a mutational 'hot-spot' on the transthyretin molecule associated with FAP arayloidogenesis
58. Orthotopic liver transplantation for familial amyloidotic polyneuropathy: The U.K. experience
59. X-ray crystal structure of the Ala-109-Thr variant of human transthyretin which produces euthyroid hyperthyroxinemia
60. Impact of age and amyloidosis on thiol conjugation of transthyretin in hereditary transthyretin amyloidosis
61. The crystal structure of transthyretin from chicken
62. Common core structure of amyloid fibrils by synchrotron X-ray diffraction
63. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters
64. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type)
65. Structure of Met30 variant of transthyretin and its amyloidogenic implications
66. Modifications of transthyretin in amyloid fibrils: Analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation
67. Crystal structure of rat transthyretin at 2.5A resolution: First report on a unique tetrameric structure
68. Mechanism of molecular recognition. Structural aspects of 3,3'-diiodo-L-thyronine binding to human serum
69. Structural aspects of inotropic bipyridine binding. Crystal structure determination to 1.9 A resolution of the human serum transthyretin-milrinone complex
70. Structures of human transthyretin complexed with thyroxine at 2.0A resolution and 3',5'-dinitro-N-acetyl-L-thyronine at 2.2 A resolution
71. Crystal structure of transthyretin-retinoic-acid complex